GenSight

1 stories · following the connections

Business

GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy

By Nasdaq OMXFeb 29, 2016, 12:00 PM UTC